Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328246 | 0.80 | HTR2A (0.49) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL18202247 | 0.76 | HTR2A (0.47) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL19921285 | 0.76 | HTR2A (0.47) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8328457 | 0.72 | HTR2A (0.55) | HTR2AHTR2CNOTUMTSHRSIGMAR1 | |
| SCHEMBL8322785 | 0.72 | HTR2A (0.47) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8328872 | 0.72 | HTR2A (0.47) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8328030 | 0.70 | HTR2A (0.39) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL18911628 | 0.69 | HTR2A (0.50) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL18911621 | 0.69 | HTR2A (0.73) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL31487068 | 0.68 | HTR2A (0.57) | HTR2AHTR2CNOTUMPOLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | HTR2A 80/4885HTR2C 81/4885NOTUM 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.